▲ Brinzolamide 1%/timolol 0.5% fixed combination (brinzolamide/timolol) is a twice-daily eyedrops suspension comprising the carbonic anhydrase-II inhibitor brinzolamide and the β-adrenergic receptor antagonist timolol.
▲ Brinzolamide/timolol produced clinically relevant reductions in mean intraocular pressure (IOP) from baseline and was more effective than brinzolamide or timolol monotherapy in lowering IOP in a 6-month, randomized, phase III trial in patients with open-angle glaucoma or ocular hypertension (n = 523). The proportion of patients achieving a mean IOP of <18 mmHg was significantly greater in recipients of brinzolamide/timolol than in recipients of brinzolamide or timolol monotherapy.
▲ The IOP-lowering efficacy of brinzolamide/timolol was maintained for up to 12 months, and was no less effective than dorzolamide 2%/timolol 0.5% solution (dorzolamide/timolol) in a randomized, phase III, noninferiority trial (n = 437).
▲ Brinzolamide/timolol was generally well tolerated and was associated with significantly lower ocular discomfort scores than dorzolamide/timolol. Moreover, a significantly greater number of patients expressed a preference for brinzolamide/timolol over dorzolamide/timolol. The main ocular adverse event was blurred vision, and was not considered to be a safety issue.
KeywordsGlaucoma Retinal Nerve Fibre Layer Aqueous Humour Timolol Ocular Hypertension
Acknowledgements and Disclosures
This manuscript was reviewed by: G. Manni, Ophthalmology Department, University of Roma, Roma, Italy; F. Ziemssen, University Eye Hospital, Centre of Ophthalmology, Eberhard Karl University, Tuebingen, Germany
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
- 2.Glaucoma Research Foundation. African-Americans and glaucoma [online]. Available from URL: http://www.glaucoma.org/learn/africanamerican.php [Accessed 2009 Feb 12]
- 6.Glaucoma Research Foundation. Are you at risk for glaucoma? [online]. Available from URL: http://www.glaucoma.org/learn/are_you_at_risk.php [Accessed 2009 Feb 12]
- 7.The Eye Digest: University of Illinois Eye & Ear Infirmary. Glaucoma causes optic nerve cupping (atrophy) and vision loss [online]. Available from URL: http://www.agingeye.net/glaucoma/glaucomainformation.php [Accessed 2009 Feb 13]
- 11.The Royal College of Ophthalmologists. A national research strategy for ophthalmology (March 2002) [online]. Available from URL: http://www.rcophth.ac.uk/docs/publications/published-guidelines/EyeResearchFinal.pdf [Accessed 2009 Feb 5]
- 12.European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. Savona, Italy: Dogma, 2008Google Scholar
- 13.Japan Glaucoma Society. Guidelines for glaucoma [online]. Available from URL: http://www.ryokunaisho.jp/english/Guidelines_for_Glaucoma.pdf [Accessed 2009 Feb 13]
- 16.International Council of Ophthalmology. Primary open-angle glaucoma (initial evaluation) [online]. Available from URL: http://www.icoph.org/guide/guidepri.html [Accessed 2009 Feb 13]
- 19.Iester M. Brinzolamide. Expert Opin. Pharmacother 2008; 9(4): 653–62Google Scholar
- 24.European Agency for the Evaluation of Medicinal Products. Brinzolamide/timolol: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/azarga/H-960-PI-en.pdf [Accessed 2009 Feb 2]
- 31.Vold SD, Evans RM, Stewart RH, et al. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2008; 24(6): 601–5PubMedCrossRefGoogle Scholar